AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701

Oncogenically active MYD88 mutations in human lymphoma

Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,560

IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples

Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

Minegishi, Y., Saitō, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pašić, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,075

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 934

Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein

Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897

Oncogene Addiction

Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805

SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity

Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P. E., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 724

Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation

Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer

Grandis, J. R., Skorupski, K. A., Cheng, N., Cui, Z., Li, H., Woerner, L. C., Gencel‐Augusto, J., Zeng, Y., Shiah, J. V., Bhola, N. E., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.015 · Cited by 12

Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products

Calderon, J. J., Prieto, K., Lasso, P., Susana Fiorentino, G., & Barreto, A. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00681-0 · Cited by 15

Role of cancer-associated fibroblasts in the progression, therapeutic resistance and targeted therapy of oesophageal squamous cell carcinoma

Xue, M., Tong, Y., Xiong, Y., & Yu, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257266 · Cited by 12

Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles

Hsu, C., Mustafa, M. A., Kumar, A., Pramanik, A., Sharma, R., Mohammed, F., Jawad, I. A., Mohammed, I. J., Alshahrani, M. Y., Khalil, N. A. M. A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155266 · Cited by 13

Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation

Hu, H., Bai, H., Huang, L., Yang, B., & Zhao, H. (2023) · Molecules · doi:10.3390/molecules28073143 · Cited by 12

STAT3 inhibition for cancer therapy: Cell-autonomous effects only?

Kroemer, G., Galluzzi, L., & Zitvogel, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1126063 · Cited by 12

Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies

Amer, H., Kampan, N. C., Itsiopoulos, C., Flanagan, K. L., Scott, C. L., Kartikasari, A. E. R., & Plebanski, M. (2024) · Cancers · doi:10.3390/cancers16244187 · Cited by 12

Antisense oligonucleotides-based approaches for the treatment of multiple myeloma

Oprea, M., & Ionita, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139186 · Cited by 13

Enhancement of antitumor effect of radiotherapy via combination with Au@SiO2 nanoparticles targeted to tumor-associated macrophages

Kim, M. S., Lee, J. S., Kim, J. E., Kim, J.-W., Bok, S., Keum, K. C., Koh, W., & Koom, W. S. (2020) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2020.01.017 · Cited by 11

STAT6-targeting antisense oligonucleotides against solitary fibrous tumor

Li, Y., Mondaza-Hernandez, J. L., Moura, D. S., Revenko, A. S., Tolentino, A., Nguyen, J. T., Tran, N., Meyer, C. A., Merino-Garcia, J. A., Ramos, R. F., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102154 · Cited by 11

Well-Defined DNA–Polymer Miktoarm Stars for Enzyme-Resistant Nanoflares and Carrier-Free Gene Regulation

Li, H., Li, Y., Xiao, Y., Zhang, B., Cheng, Z., Shi, J., Xiong, J., Li, Z., & Zhang, K. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00017 · Cited by 11

Synthesis and biological evaluation of sialyl-oligonucleotide conjugates targeting leukocyte B trans-membranal receptor CD22 as delivery agents for nucleic acid drugs

St‐Pierre, G., Pal, S., Østergaard, M. E., Zhou, T., Yu, J., Tanowitz, M., Seth, P. P., & Hanessian, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.047 · Cited by 11

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor

Lee, D. S., O’Keefe, R. A., Ha, P. K., Grandis, J. R., & Johnson, D. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061608 · Cited by 11

Aberrant pre-mRNA processing in cancer

Biswas, J., Boussi, L. S., Stein, E. M., & Abdel-Wahab, O. I. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230891 · Cited by 10

An Isoxazoloquinone Derivative Inhibits Tumor Growth by Targeting STAT3 and Triggering Its Ubiquitin-Dependent Degradation

Xie, Y., Zhu, S., Chen, L., Liu, H., Peng, T., Ming, Z., Zou, Z., Hu, X., Luo, W., Peng, K., et al. (2023) · Cancers · doi:10.3390/cancers15092424 · Cited by 10

Hypermethylation of antisense long noncoding RNAs in acute lymphoblastic leukemia

Arthur, G., Almamun, M., & Taylor, K. H. (2017) · Epigenomics · doi:10.2217/epi-2016-0156 · Cited by 10

Generation of an inducible mouse model to reversibly silence Stat3

Alorro, M., Pierce, T. P., Eissmann, M. F., Dijkstra, C., Dickins, R. A., Ernst, M., Büchert, M., & Masson, F. (2017) · genesis · doi:10.1002/dvg.23023 · Cited by 10

Myeloid-Derived Suppressor Cells and Pulmonary Hypertension

Bryant, A. J., Mehrad, B., Brusko, T. M., West, J. D., & Moldawer, L. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082277 · Cited by 10

Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides

van Tran, N., Nguyen, L. T. A., Lim, K. W., & Phan, A. T. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2000108 · Cited by 12

Genetic Drivers of Head and Neck Squamous Cell Carcinoma: Aberrant Splicing Events, Mutational Burden, HPV Infection and Future Targets

Dlamini, Z., Alaouna, M., Mbatha, S. Z., Bhayat, A., Mabongo, M., Chatziioannou, A. A., & Hull, R. (2021) · Genes · doi:10.3390/genes12030422 · Cited by 11

ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression

Liu, J.-P. (2024) · American Journal of Cancer Research · doi:10.62347/lodv2387 · Cited by 9

Targeting Molecular Signaling Pathways and Cytokine Responses to Modulate c-MYC in Acute Myeloid Leukemia

Gu, K. J., May, H. A., & Kang, M. H. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1603015 · Cited by 9

STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes

King, Z., Desai, S. R., Frank, D. A., & Shastri, A. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101137 · Cited by 11

Cell Type-Specific Roles of STAT3 Signaling in the Pathogenesis and Progression of K-ras Mutant Lung Adenocarcinoma

Clowers, M. J., & Moghaddam, S. J. (2022) · Cancers · doi:10.3390/cancers14071785 · Cited by 9

The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases

Paul, D., Miller, M. H., Born, J. R., Samaddar, S., Ni, H., Avila, H., Krishnamurthy, V. R., & Thirunavukkarasu, K. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2160439 · Cited by 9

Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress

Andrés, C., de la Lastra, J. M. P., Juan, C., Plou, F. J., & Pérez‐Lebeña, E. (2023) · Vaccines · doi:10.3390/vaccines11020218 · Cited by 9

Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice

Kaufmann, B. K., Jiménez, M. D. L. R., Booshehri, L. M., Onyuru, J., Leszczynska, A., Uri, A., Michel, S., Klar, R., Jaschinski, F., Feldstein, A. E., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200550 · Cited by 9

Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer

Liu, Z.-Y., Zhang, Y.-W., Zhuang, H.-X., Ou, Y.-J., Jiang, Q.-Y., Li, P.-F., He, Y., Ren, Y., & Mao, X. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01366-w · Cited by 9

At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma

Wondergem, N. E., Nijenhuis, D. N. L. M., Poell, J. B., Leemans, C. R., Brakenhoff, R. H., & van de Ven, R. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.647980 · Cited by 9

Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice

Wang, D., Kaniowski, D., Jacek, K., Su, Y., Yu, C., Hall, J., Li, H., Feng, M., Hui, S. K., Kaminska, B., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102268 · Cited by 8

Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects

Ziółkowska‐Suchanek, I., & Rozwadowska, N. (2025) · Genes · doi:10.3390/genes16050569 · Cited by 10

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1

Darman, L., Kaurich, Q., Hassan, S., von Holzen, U. W., & Awasthi, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110755 · Cited by 9

Natural antisense transcript of MYOG regulates development and regeneration in skeletal muscle by shielding the binding sites of MicroRNAs of MYOG mRNA 3′UTR

Yin, Y., Chen, G., Lin, Z., Zhang, D., Lin, W., & Luo, W. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.050 · Cited by 8

Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma

Dong, L., Liu, C., Sun, H., Wang, M., Sun, M., Zheng, J., Yu, X., Shi, R., Wang, B., Zhou, Q., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216956 · Cited by 8

Targeting the Depletion of M2 Macrophages: Implication in Cancer Immunotherapy

Festekdjian, T., & Bonavida, B. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053580 · Cited by 8

Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma

Barth, M. J., & Minard‐Colin, V. (2019) · British Journal of Haematology · doi:10.1111/bjh.15783 · Cited by 8

Antisense Therapy: An Overview

Sharad, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86867 · Cited by 8

Engineered adult stem cells: a promising tool for anti-cancer therapy

Choi, Y., Lee, H. K., & Choi, K. (2023) · BMB Reports · doi:10.5483/bmbrep.2022-0091 · Cited by 8

Sonic hedgehog signaling: Alternative splicing and pathogenic role in medulloblastoma

Qu, M., He, Q., Luo, J., Shen, T., Gao, R., Xu, Y., Xu, C., Barkat, M. Q., Zeng, L., & Wu, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.10.014 · Cited by 8

LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy

Ray, S. K., & Mukherjee, S. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009620666210106122421 · Cited by 8

Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review)

Cheng, H., Chen, L., & Huang, C. (2025) · Oncology Letters · doi:10.3892/ol.2025.14881 · Cited by 7

Chemical Modifications in Nucleic Acid Therapeutics

Lennox, K. A., Young, R. C., & Behlke, M. A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_3 · Cited by 8

Harnessing microRNAs in lung cancer: The future of diagnosis and precision therapy

Alexandre, D., Baptista, P. V., & Cruz, C. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189535 · Cited by 7

Advances in oligonucleotide therapeutics: recent bench-side progress in ASO, siRNA, and aptamer

Li, Y., Ding, F., Zhu, L., Feng, H., & Zhang, C. (2026) · Materials Today · doi:10.1016/j.mattod.2026.103204 · Cited by 7

Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches

Ou, Y., Wei, H., Peng, C., Li, J., Wei, K., Zhan, C., & Zhang, Z. (2026) · Cancers · doi:10.3390/cancers18060980 · Cited by 8

Advances in RNA therapeutics for modulation of ‘undruggable’ targets

Martinsen, E., Jinnurine, T., Subramani, S., & Rogne, M. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.003 · Cited by 7

RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials

Hsia, T., & Chen, Y. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114234 · Cited by 7

The Use of Zebrafish Xenotransplant Assays to Analyze the Role of lncRNAs in Breast Cancer

Zampedri, C., Martínez-Flores, W. A., & Meléndez-Zajgla, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.687594 · Cited by 7

Contract to kill: GNAS mutation

Raut, P., Mathivanan, P., Batra, S. K., & Ponnusamy, M. P. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02247-4 · Cited by 6

LINC00654 confers sorafenib resistance by suppressing ferroptosis via STAT3-mediated transcriptional activation of SLC7A11 in hepatocellular carcinoma

Peng, H., Xu, A., Sun, C., Tong, F., Kang, X., Zhou, H., Kang, J., Li, X., Han, Y., Xue, C., et al. (2023) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2023.131458 · Cited by 6

Lung cancer treatment potential and limits associated with the STAT family of transcription factors

Faida, P., Attiogbe, M. K. I., Majeed, U., Zhao, J., Qu, L., & Fan, D. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110797 · Cited by 6

Clickable polyethyleneimine incorporated into triblock copolymeric micelles as an efficient platform in the delivery of siRNA to NSCLC cells

Marquet, F., Hagen, H., Stanchieri, M., Serre‐Beinier, V., Grasso, G., Danani, A., Patrulea, V., & Borchard, G. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123632 · Cited by 6

Noncoding RNA-Targeted Therapeutics in Autoimmune Diseases: From Bench to Bedside

Zhang, Z., Yao, Z., & Zhang, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809912-4.00017-9 · Cited by 7

STAT3-driven EMT in cancer metastasis and chemoresistance: A review

Tian, Y., Tang, M., Qiao, M., Wang, X., Huang, Y., Luo, T., Nabavi, N., Ashrafizadeh, M., Cheng, H., & Tu, Y. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151403 · Cited by 5

Cytokines and cancer-associated fibroblasts

Hu, Y., Liang, J.-J., Duan, L., Zhu, J., Shan, G., Cheng, T., Wu, Y., Tan, L., & Zhan, C. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01801-x · Cited by 6

Roles of STAT3 and STAT Family Proteins and Their Signaling Pathways in Thyroid Cancer

Masaki, C., Inoue, N., & Chiba, T. (2026) · Cells · doi:10.3390/cells15100884 · Cited by 5

Beyond the horizon: Neutrophils leading the way in the evolution of immunotherapy

Rajgopal, S., Nakano, K., & Cook, L. M. (2023) · Cancer Medicine · doi:10.1002/cam4.6761 · Cited by 5

Immune Evasion in Cancer Is Regulated by Tumor-Asociated Macrophages (TAMs): Targeting TAMs

Jung, M., & Bonavida, B. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053096 · Cited by 5

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma

Clay, T. D., Russell, P. A., Do, H., Sundararajan, V., Conron, M., Wright, G. M., Solomon, B., Dobrovic, A., McLachlan, S., & Moore, M. M. (2017) · Medical Oncology · doi:10.1007/s12032-017-1031-1 · Cited by 5

Prevention of STAT3-related pathway in SK-N-SH cells by natural product astaxanthin

Sun, S., Du, F.-X., Zhang, L., Hao-Shi, Gu, F.-Y., Deng, Y., & Ji, Y. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04267-3 · Cited by 5

Structurally Dynamic Polyplexes Enhance Sentinel Lymph Node Delivery of Antisense Oligonucleotides to Inhibit Breast Cancer Recurrence and Metastasis

Lau, C. Y. J., Kinoh, H., Liu, X., Feng, J., Aulia, F., Taniwaki, K., Qiao, N., Ogura, S., Naito, M., & Miyata, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04234 · Cited by 4

STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome

Pellerino, A., Priego, N., Bertero, L., Ricci, A. A., Mangherini, L., Bruno, F., Beano, A., Mittica, G., Mistrangelo, M., Garbossa, D., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf187 · Cited by 4

Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress–mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma

Chang, W.-H., Liao, W., Yeh, T., Moi, S., Liu, Y., Hsiao, H., Wang, H., Du, J., Gau, Y., Yang, C.-I., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07252-1 · Cited by 7

Molecularly targeted therapy and immunotherapy in leukemias

Cousin, É., Picard, A., Oundjian, M., Tardif, N., Quéméner, A. M., Rio, A.-G., Galibert, M., Gandemer, V., & Mazurier, F. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01775-2 · Cited by 4

Biological roles and molecular mechanism of circular RNAs in epithelial-mesenchymal transition of gastrointestinal malignancies

HU, M., Fang, Z., Shao, Y., Yan, J., & Ye, G. H. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.051589 · Cited by 5

Systematic drug screening and target analysis identify digitoxin as a potential therapy for uveal melanoma

Liu, H., Huang, C., Liu, Z., Li, Y., Zhu, Y., Gao, M., Chen, J., Zhang, H., Xiao, Z., & Zhao, W. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17405 · Cited by 4

A novel synthesised STAT3 inhibitor exerts potent anti‐tumour activity by inducing lysosome‐dependent cell death

Xu, M. X., Liu, X., Zhang, H., Xu, H., Ma, X., Yang, Y., Duan, C., Tang, S., Liu, Y., Li, C., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70071 · Cited by 4

The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma

Tang, D., Jiang, H., Li, Z., Gao, W. Y., & Sun, Y. (2020) · Neoplasma · doi:10.4149/neo_2020_200530n586 · Cited by 4

Exploring the immunological role and prognostic potential of PPM1M in pan-cancer

Zeng, R., Wang, L., Zhang, Y., Yang, Y., Yang, J., & Qin, Y. (2023) · Medicine · doi:10.1097/md.0000000000032758 · Cited by 3

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T‐cell lymphoma

Wang, Y., Zhou, W., Chen, J., Chen, J., Deng, P., Chen, H., Sun, Y.-C., Yu, Z., Pang, D., Liu, L., et al. (2023) · MedComm · doi:10.1002/mco2.284 · Cited by 4

Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy

Soldevilla, M. M., & Pastor, F. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.006 · Cited by 4

Jak/STAT Signaling in Head and Neck Cancer

Cedars, E., Johnson, D. E., & Grandis, J. R. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_6 · Cited by 4

Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents

Scott, L. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-75184-9_6 · Cited by 4

Advances in antisense oligonucleotide treatment for cancer

Zhu, L., Muhtar, P., Goyama, S., & Yoshimi, A. (2026) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyag017 · Cited by 3

Synthesis of 7’‐Substituted 2’‐O‐4’‐C‐Ethylene Bridged Nucleic Acid (ENA)‐Thymidine Monomers

Prabhakar, S., Gaurrand, S., Lambert, É., Guillemont, J., Beigelman, L. N., Brioche, J. C. R., & Piettre, S. R. (2023) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202300946 · Cited by 3

Unveiling the intricacy of gapmer oligonucleotides through advanced tandem mass spectrometry approaches and scan accumulation for 2DMS

Rahman, M. K., Marzullo, B. P., Lam, Y. P. Y., Barrow, M. P., Holman, S. W., Ray, A. D., & O’Connor, P. B. (2024) · The Analyst · doi:10.1039/d4an00484a · Cited by 7

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

Pophali, P. A., Desai, S. R., & Shastri, A. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00693-9 · Cited by 3

Prognostic and therapeutic potential of STAT3: Opportunities and challenges in targeting HPV-mediated cervical carcinogenesis

Janjua, D., Thakur, K., Aggarwal, N., Chaudhary, A., Yadav, J., Chhokar, A., Tripathi, T., Joshi, U., Senrung, A., & Bharti, A. C. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104346 · Cited by 3

Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma

Lazzari, C., Verlicchi, A., Γκουντάκος, Α., Pilotto, S., Santarpía, M., CHAIB-OUKADOUR, I., Ramírez, J. L., Viteri, S., Morales-Espinosa, D., Dazzi, C., et al. (2016) · Pulmonary Therapy · doi:10.1007/s41030-016-0013-3 · Cited by 4

PROGRESS OF OLIGONUCLEOTIDE THERAPEUTICS TARGET TO RNA

Pan, Y., Zhou, X., & Yang, Z. (2022) · Wiley eBooks · doi:10.1002/9781119692799.ch11 · Cited by 3

The Role of STAT3 in Cancer: From Metabolic Regulation to Therapeutic Targeting

Ashourpour, M., Mohammadian, J., Mehdizadeh, A., Nour, M. A., & Ghorbanihaghjo, A. (2025) · Biofactors · doi:10.1002/biof.70045 · Cited by 2

APOL1-mediated kidney disease: a narrative review of the lessons learnt from the past 15 years

Adebayo, O. C., Okpoli, H. C., Vriens, J., Levtchenko, E. N., van den Heuvel, L. P., & Labarque, V. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04687-y · Cited by 2

JAK-STAT pathway in hematological malignancies: Achievements, challenges and future perspectives

Pan, B., Shi, K., Li, Y., Wang, X., Song, C., Zhang, Q., & Li, L. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118959 · Cited by 2

The RAvIN Platform: A Noncarbohydrate Platform for Oligonucleotide Synthesis

Nodwell, M. B., Caballero‐García, G., Mesa, J. M., Muilu, T., Wilson, D. M., Arora, A., Brooke, A. J., Singgh, B., Gill, M., Tran, H. M., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c21938 · Cited by 2

Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress

Chen, H., Fu, R., & Wu, Z. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01877-8 · Cited by 3

Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy

Tomás‐Roca, L., Rodríguez, M., Alonso‐Alonso, R., Rodríguez-Pinilla, S. M., & Piris, M. A. (2021) · Hemato · doi:10.3390/hemato2020017 · Cited by 2

BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment

Gagliardi, M., Kean, R. B., Dai, B., Augustine, J. J., Roberts, M., Fleming, J. B., Hooper, D. C., & Ashizawa, A. T. (2024) · Biomedicines · doi:10.3390/biomedicines12081901 · Cited by 2

Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future

Hall, J., Ashkinadze, A., Becker, J. P., Łaski, A., Manz, E.-M., Moravčík, Š., Sjöström, S., & Vincent, M. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.466 · Cited by 2

Historical Development of STAT3 Inhibitors and Early Results in Clinical Trials

Yu, C., Jove, R., & Turkson, J. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_4 · Cited by 2

Progress of JAK/STAT 3 and its inhibitors in the treatment of cancer

Hu, W. (2020) · AIP conference proceedings · doi:10.1063/5.0000440 · Cited by 2

A modular approach to enzymatic ligation of peptides and proteins with oligonucleotides

Tan, D. J. Y., Cheong, V. V., Lim, K. W., & Phan, A. T. (2021) · Chemical Communications · doi:10.1039/d1cc01348c · Cited by 2

Investigating the Frontiers of Genetic Regulation and Unlocking the Secrets of Gene Expression: The Power of RNA-based Therapeutics

Muhammed Ali Siham, H. R. (2023) · doi:10.37191/mapsci-jcgh-1(1)-002 · Cited by 1

Bazedoxifene Inhibits Cell Viability, Colony‐Forming Activity, and Cell Migration in Human Non – Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine

Huang, Y., Lin, J., Fu, X., Li, L., & Fu, S. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13822 · Cited by 1

Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer

Liu, Y., Chen, Z., Duan, Y., Shao, Z., Chen, Y., Yang, N., Xiao, H., Li, Y., & Song, K. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03079-1 · Cited by 1

Sensitisation of HeLa Cell Cultures to Xanthone Treatment by RNAi-Mediated Silencing of NANOG and STAT3

Gruszka, O., Żelaszczyk, D., Marona, H., & Bednarek, I. A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070529 · Cited by 1

RNA N4-acetylcytidine modification in gastrointestinal cancer: Novel functions, mechanisms, and therapeutic implications

Lu, J., Gao, Y., Li, Q., Jiao, Y., Bian, Y., Lin, H., Lei, X., Wang, W., Li, Z., & Wang, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104867 · Cited by 1

Development of Synthetic Routes to 2′‐ O ,4′‐ C ‐Spirocyclopentylene‐Bridged Nucleic Acids: Thymidine, Guanosine, and Adenosine

Kumagai, R., Yamada, R., Yamaguchi, T., & Obika, S. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202502995 · Cited by 2

Out of Nucleus: Serine 727 Phosphorylation Orchestrates Non-Canonical STAT3 Functions—Relevance to Triple-Negative Breast Cancer

Viavattene, D., Marchetti, A. R., Schael, N., & Poli, V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052242 · Cited by 2

T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype

Schultz, A. B., Dalzell, M., Nivelo, L. A., Henrickson, S. E., & Villarino, A. V. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1726565 · Cited by 1

Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies

Drosos, C., Kapsi, A., Nikolaidou, A., & Giakountis, A. (2026) · Cancers · doi:10.3390/cancers18152497 · Cited by 1

Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3

Hong, D. S., Kim, Y., Younes, A., Nemunaitis, J. J., Fowler, N. H., Hsu, J., Zhou, T., Fayad, L., Zhang, N., Piha-Paul, S. A., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-lb-227 · Cited by 5

Abstract LB-317: Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models.

Kim, Y., Hsu, J., Zhou, T., Zhang, N., Woessner, R. D., Nadella, M. V. P., Lawson, D., Reimer, C., He, G., Schmidt, J., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-317 · Cited by 2

Blocking transcription in tumors, STAT

Nusinovich, Y. A. (2015) · Science Signaling · doi:10.1126/scisignal.aad9035

Strong pharmacological activity of locally administered next-generation antisense oligonucleotides (ASOs) in orthotopic lung cancer mouse models

Jo, M., Schmidt, J., Zhou, T., Wu, X., Crosby, J. R., Brand, E., Kim, Y., & MacLeod, A. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.043 · Cited by 1

Abstract C136: Exploring the functional contribution of STAT3 activity in tumor and tumor-associated stromal cells with species-selective generation 2.5 antisense oligonucleotides in preclinical cancer models.

Hsu, J., He, G., Bhattacharjee, G., Zhou, T., Kim, Y., Monia, B. P., & MacLeod, R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c136